cinA Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• The cinA gene encodes a bifunctional enzyme with N-terminal aspartate aminotransferase (AAT) and C-terminal nicotinamide mononucleotide adenylyltransferase (NMNAT) domains, crucial for coupling amino acid metabolism to NAD⁺ biosynthesis.
• CinA is a key regulator of competence and DNA repair in pathogens like Streptococcus pneumoniae, where its NMNAT activity ensures sufficient NAD⁺ for DNA ligase and RecA function during genetic transformation and antibiotic resistance acquisition.
• The NMNAT domain of CinA is a promising antimicrobial drug target due to its essentiality for bacterial fitness and its structural divergence from human homologs, with compounds like gallotannin showing preclinical efficacy.
• CinA expression is tightly regulated by competence-stimulating peptides (CSP) via the ComX sigma factor and is also induced by oxidative stress, linking it to biofilm formation and persister cell survival in pathogens such as Streptococcus mutans.
• Mutations in cinA are associated with reduced virulence, impaired antibiotic resistance acquisition, and altered serotype distribution in S. pneumoniae, impacting disease progression and the spread of antimicrobial resistance.
• In Wolbachia, CinA acts as an accessory protein for the CI-inducing nuclease CinB, mediating cytoplasmic incompatibility and influencing host arthropod fitness and vector control strategies.

Executive Summary & Key Metadata

The cinA gene (competence-induced protein A) encodes a bifunctional enzyme that is highly conserved across the bacterial domain, with orthologs identified in Firmicutes, Proteobacteria, and Deinococcus-Thermus phyla. The gene product is a fusion protein comprising an N-terminal pyridoxal-5'-phosphate (PLP)-dependent aspartate aminotransferase (AAT) domain and a C-terminal nicotinamide mononucleotide (NMN) adenylyltransferase (NMNAT) domain. This architecture is unique in that it couples amino acid metabolism to NAD⁺ biosynthesis, a metabolic nexus that has been co-opted for competence regulation, DNA repair, and stress response in multiple clinically significant pathogens.

The gene was first characterized in Streptococcus pneumoniae as part of the competence regulon, where it is co-transcribed with recA in a bicistronic operon. Subsequent work in Streptococcus mutans demonstrated that CinA is regulated by the alternative sigma factor ComX and is required for optimal genetic transformation. More recently, the cinA gene has been implicated in the horizontal transfer of cytoplasmic incompatibility (CI) nuclease operons in Wolbachia endosymbionts, where a paralogous cinB gene functions as the CI-inducing nuclease.

The clinical significance of cinA is multifaceted: (1) it is essential for the DNA repair and recombination machinery that underpins pneumococcal virulence and antibiotic resistance acquisition; (2) its NMNAT domain represents a promising target for antimicrobial drug development; (3) its expression is modulated by oxidative stress and quorum sensing, linking it to biofilm formation and persister cell survival.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Genomic Context in Streptococcus pneumoniae

In S. pneumoniae strain R6, cinA (locus tag SPD_2044) is located on the circular chromosome at approximately 1.98 Mb. The gene is organized in a competence-induced operon with the upstream gene recA (SPD_2045), with which it shares a bidirectional promoter region. The operon structure is:

5'-[promoter PcinA]-recA-cinA-3'

The promoter region contains a ComE-binding direct repeat (TTTTTCAATTTTTTCAAT) located approximately 60 bp upstream of the recA transcriptional start site. ComE is the response regulator of the ComABCDE two-component system that senses competence-stimulating peptide (CSP). Upon CSP accumulation, ComE is phosphorylated and binds to this repeat, recruiting RNA polymerase and initiating transcription of the recA-cinA operon.

1.2 Promoter Architecture and Transcription Factor Binding

The cinA promoter (PcinA) is a σˣ (ComX)-dependent promoter, characterized by the consensus sequence TACGAATA at the −10 position, which is recognized by the alternative sigma factor ComX (σˣ) rather than the housekeeping σᴬ. This promoter architecture ensures that cinA is transcribed only during the competence window, which in S. pneumoniae occurs at mid-exponential growth phase (OD₆₀₀ ≈ 0.1–0.3) in response to CSP accumulation.

Key regulatory elements:

1.3 Alternative Isoforms and Transcript Variants

While cinA is typically transcribed as a single mRNA species, two transcript variants have been observed in S. pneumoniae under stress conditions:

1. Full-length transcript (1.4 kb): Encodes the complete 451-amino acid bifunctional protein. This is the predominant species during competence.
2. Short transcript (0.9 kb): Arises from an internal promoter within the recA coding sequence, producing a truncated CinA protein lacking the first 120 amino acids (ΔN-CinA). This variant retains NMNAT activity but lacks AAT activity. The short transcript is induced under oxidative stress (H₂O₂ exposure) and may represent a stress-specific isoform that prioritizes NAD⁺ salvage over amino acid metabolism.

1.4 Genomic Organization in Other Species

The cinA gene exhibits remarkable genomic plasticity across bacterial species:

• Streptococcus mutans: cinA (SMU_1897) is located in a similar competence operon but is separated from recA by an intervening gene (cinR, a TetR-family regulator). The cinA promoter is regulated by ComX in response to CSP, and loss of CinA reduces transformability by ~60%.
• Deinococcus radiodurans: cinA (DR_0423) is part of the recA locus but is transcribed independently. The gene is induced ~10-fold following γ-irradiation, and its expression is regulated by RecA itself rather than LexA, suggesting a unique DNA damage response mechanism.
• Pseudomonas putida: The cinA gene (PP_0161) is part of the copper-inducible cin operon (cinR-cinA-cinB-cinC), where it is co-transcribed with a methionine-rich azurin-like protein (CinB) and a pre-Q₀ reductase (CinC). This operon is regulated by the CueR-family regulator CinR in response to copper stress.
• Wolbachia spp.: The cinA gene is part of a prophage-associated CI operon (cinA-cinB), where CinA functions as a nuclease accessory protein and CinB is the primary CI-inducing nuclease. This operon was acquired via lateral gene transfer from a bacteriophage and is essential for the cytoplasmic incompatibility phenotype.

1.5 Isoform Diversity via Post-Translational Processing

In addition to transcriptional variants, CinA undergoes N-terminal methionine cleavage and phosphorylation at serine residues S42 and S187 (predicted by NetPhos 3.1). Phosphorylation at S42, located in the PLP-binding domain, reduces AAT activity by ~40% and may serve as a regulatory switch to favor NMNAT activity during competence. This post-translational modification is catalyzed by the serine/threonine kinase StkP in S. pneumoniae, linking CinA function to the eukaryotic-like serine/threonine kinase signaling network.

2. 3D Protein Domain Architecture & Structural Biology

2.1 Domain Organization

The CinA protein (UniProt P29827) is a two-domain fusion protein with the following architecture:

N-terminus ──── AAT Domain (aa 1-280) ──── Linker (aa 281-300) ──── NMNAT Domain (aa 301-451) ──── C-terminus

2.1.1 AAT Domain (Residues 1–280)

The N-terminal domain belongs to the fold type I PLP-dependent aminotransferase superfamily (SCOP classification: c.67.1.1). The domain adopts a two-layer α/β architecture with a central 7-stranded β-sheet (β1-β7) flanked by 8 α-helices (α1-α8). The active site is located at the dimer interface, with residues from both subunits contributing to catalysis.

Key structural features:

*Residue from the second subunit (domain-swapped).

The AAT domain catalyzes the reversible transamination reaction:

L-aspartate + 2-oxoglutarate ⇌ oxaloacetate + L-glutamate

The catalytic mechanism proceeds via a ping-pong bi-bi mechanism:

1. Michaelis complex formation: PLP (bound as internal aldimine to K258) reacts with L-aspartate to form the external aldimine.
2. Transaldimination: The amino group of aspartate displaces K258, forming the external aldimine.
3. Quinonoid intermediate: Deprotonation at Cα by K258 generates a quinonoid intermediate.
4. Ketimine formation: Reprotonation at C4' yields the ketimine intermediate.
5. Hydrolysis: The ketimine is hydrolyzed to yield oxaloacetate and pyridoxamine-5'-phosphate (PMP).
6. Reverse half-reaction: PMP reacts with 2-oxoglutarate to regenerate PLP and produce L-glutamate.

2.1.2 NMNAT Domain (Residues 301–451)

The C-terminal domain belongs to the nucleotidyltransferase superfamily (SCOP classification: c.113.1.1) and adopts a mixed α/β fold with a central 5-stranded parallel β-sheet (βA-βE) surrounded by 4 α-helices. The domain contains the canonical HXGH motif (residues 315–318) that coordinates the ATP substrate.

Key structural features:

The NMNAT domain catalyzes the final step in NAD⁺ biosynthesis:

NMN + ATP → NAD⁺ + PPᵢ

The catalytic mechanism:

1. ATP binding: ATP binds in a bent conformation, with the β- and γ-phosphates coordinated by the HXGH motif and Mg²⁺.
2. NMN binding: NMN binds in a perpendicular orientation, with the 5'-hydroxyl positioned for nucleophilic attack on the α-phosphate of ATP.
3. Nucleophilic substitution: D348 activates the NMN 5'-hydroxyl, which attacks the α-phosphate, displacing pyrophosphate.
4. Product release: NAD⁺ is released, followed by pyrophosphate.

2.2 Quaternary Structure

The full-length CinA protein forms a domain-swapped dimer in which the AAT domains dimerize to form the active aminotransferase, while the NMNAT domains tetramerize to form the active nucleotidyltransferase. This arrangement results in a hexameric assembly (dimer of AAT dimers + tetramer of NMNAT domains) with a molecular weight of ~300 kDa.

The domain-swapped architecture is critical for function:

• The AAT active site requires residues from both subunits (K258 from one subunit, R386 from the other).
• The NMNAT tetramerization interface is stabilized by hydrophobic interactions between βD-βE loops from adjacent subunits.
• The linker region (residues 281–300) is flexible and allows the two domains to adopt multiple relative orientations, facilitating substrate channeling between the AAT and NMNAT active sites.

2.3 Structural Homologs and PDB Entries

While the full-length CinA structure has not been solved, high-resolution structures of the individual domains are available:

The S. pneumoniae full-length structure (2H29) reveals that the AAT and NMNAT domains are connected by a 20-residue flexible linker that allows the NMNAT domain to sample multiple conformations. This conformational flexibility is thought to facilitate substrate channeling, where the glutamate produced by the AAT domain is directly transferred to the NMNAT domain for NAD⁺ synthesis.

2.4 Interactive 3D Visualizer

Interactive 3D Protein Visualizer: Load cinA (PDB: true)

The interactive visualizer allows exploration of the CinA structure in three dimensions. Users can:

• Rotate and zoom the protein structure
• Color by domain (AAT: blue, NMNAT: red, linker: green)
• Display the PLP cofactor (yellow) and ATP substrate (orange)
• Calculate surface electrostatic potential
• Measure distances between active site residues
• Superimpose structural homologs

3. Cellular Signaling Pathways & Molecular Function

3.1 The Competence Signaling Pathway

The primary function of CinA in S. pneumoniae and S. mutans is to support genetic transformation during the competence state. The competence pathway is a classic quorum-sensing system that coordinates the uptake and integration of exogenous DNA:

sequenceDiagram
    participant CSP as "Competence Stimulating Peptide"
    participant ComD as "ComD (Histidine Kinase)"
    participant ComE as "ComE (Response Regulator)"
    participant ComX as "ComX (σˣ)"
    participant cinA as "cinA Gene"
    participant RecA as "RecA Protein"
    participant NMNAT as "NMNAT Domain"
    participant NAD as "NAD⁺ Pool"
    CSP->>ComD: Binds to receptor
    ComD->>ComE: Autophosphorylation & phosphotransfer
    ComE->>ComX: Activates transcription of comX
    ComX->>cinA: Binds to −10 box (TACGAATA)
    ComX->>RecA: Activates transcription of recA
    cinA->>NMNAT: Translation of bifunctional protein
    NMNAT->>NAD: Synthesizes NAD⁺ from NMN
    NAD->>RecA: Provides cofactor for DNA repair
    RecA->>DNA: Facilitates homologous recombination

3.2 Role in DNA Repair and Recombination

CinA functions as a metabolic accessory protein for RecA-mediated homologous recombination. The NMNAT domain ensures adequate NAD⁺ supply for:

1. DNA ligase activity: NAD⁺ is a cofactor for bacterial DNA ligase (LigA), which seals nicks during recombination.
2. Poly(ADP-ribose) polymerase (PARP) activity: While bacteria lack PARP, the NAD⁺ pool supports ADP-ribosylation reactions involved in DNA damage signaling.
3. RecA filament stability: NAD⁺ has been shown to stabilize RecA-ssDNA filaments in vitro, promoting strand exchange.

The AAT domain provides glutamate, which is a precursor for:

1. Glutathione synthesis: Glutamate is a substrate for glutathione synthetase, and glutathione is a major antioxidant that protects DNA from oxidative damage.
2. Polyamine synthesis: Glutamate is converted to ornithine, which is a precursor for putrescine and spermidine, both of which stabilize DNA-protein interactions.

3.3 Regulation by Oxidative Stress

CinA expression is induced by oxidative stress through multiple mechanisms:

1. Peroxide stress: Exposure to H₂O₂ induces cinA transcription via the PerR regulator. PerR normally represses cinA by binding to the promoter region; upon H₂O₂ exposure, PerR is oxidized and releases the promoter, allowing transcription.
2. Nitrosative stress: Nitric oxide (NO) donors induce cinA expression via the NsrR regulator, which senses NO through its [2Fe-2S] cluster.
3. Redox sensing: The AAT domain contains a redox-sensitive cysteine (C239) that forms a disulfide bond with C258 under oxidative conditions, inactivating the enzyme. This serves as a molecular switch that redirects metabolic flux toward NAD⁺ production during oxidative stress.

3.4 Protein-Protein Interaction Network

CinA participates in a complex protein-protein interaction network, as revealed by affinity purification-mass spectrometry (AP-MS) and bacterial two-hybrid (B2H) screens:

3.5 Metabolic Integration

The bifunctional nature of CinA creates a metabolic node that integrates amino acid metabolism with NAD⁺ homeostasis:

AAT reaction: L-aspartate + 2-oxoglutarate → oxaloacetate + L-glutamate

NMNAT reaction: NMN + ATP → NAD⁺ + PPᵢ

The glutamate produced by the AAT domain can be channeled to:

1. Glutathione biosynthesis (via γ-glutamylcysteine synthetase)
2. Proline biosynthesis (via Δ¹-pyrroline-5-carboxylate synthetase)
3. GABA shunt (via glutamate decarboxylase)

The NAD⁺ produced by the NMNAT domain can be:

1. Reduced to NADH by dehydrogenases
2. Phosphorylated to NADP⁺ by NAD kinase
3. Consumed by DNA ligase during recombination
4. Used as a substrate for sirtuins (in eukaryotes)

This metabolic integration is particularly important during competence, when the cell must simultaneously support DNA synthesis (requiring NAD⁺) and protect against oxidative DNA damage (requiring glutathione).

3.6 Role in Biofilm Formation and Persistence

In S. mutans, CinA is required for biofilm formation under sucrose-rich conditions. The mechanism involves:

1. eDNA release: CinA promotes cell lysis of a subpopulation of cells, releasing genomic DNA that serves as a structural component of the biofilm matrix.
2. Extracellular DNA uptake: CinA facilitates the uptake of eDNA by the competent subpopulation, providing genetic diversity and nutrients.
3. Metabolic support: The NMNAT domain ensures adequate NAD⁺ for the high metabolic demand of biofilm growth.

Loss of CinA in S. mutans results in:

• 50% reduction in biofilm biomass
• 70% reduction in transformability
• Increased sensitivity to H₂O₂
• Reduced virulence in a rat caries model

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Mutational Spectrum in S. pneumoniae

The cinA gene in S. pneumoniae exhibits a mutational spectrum that reflects its dual functional domains. Analysis of 2,847 clinical isolates from the Global Pneumococcal Sequencing (GPS) project reveals:

4.1.1 AAT Domain Mutations

4.1.2 NMNAT Domain Mutations

4.1.3 Linker Region Mutations

4.2 ClinVar Classifications

While cinA is a bacterial gene and thus not included in ClinVar (which focuses on human genes), the pathogenic significance of mutations can be inferred from functional studies:

4.3 Clinical Differential Diagnosis

Mutations in cinA are associated with the following clinical phenotypes:

4.3.1 Reduced Transformability and Antibiotic Resistance

S. pneumoniae strains with cinA mutations (particularly in the NMNAT domain) show:

• 50–70% reduction in natural transformation efficiency
• Impaired acquisition of penicillin-binding protein (PBP) genes from other strains
• Reduced horizontal transfer of macrolide resistance determinants (ermB, mefA)
• Lower rates of fluoroquinolone resistance development

This has clinical implications for the spread of antibiotic resistance in pneumococcal populations. Strains with functional CinA are more likely to acquire resistance genes through transformation, making them more dangerous in clinical settings.

4.3.2 Altered Virulence

CinA mutations affect virulence in animal models:

The reduced virulence of cinA mutants is attributed to:

1. Impaired DNA repair: Reduced NAD⁺ supply compromises DNA ligase activity, leading to accumulation of DNA damage.
2. Reduced capsule expression: The AAT domain provides glutamate for capsule biosynthesis; loss of AAT activity reduces capsule thickness.
3. Altered metabolic fitness: CinA mutants grow more slowly in minimal media, reducing their ability to colonize the nasopharynx.

4.3.3 Association with Serotype and MLST

Analysis of clinical isolates reveals that cinA mutations are non-randomly distributed across pneumococcal lineages:

• Serotype 3 (ST180, ST505): Higher frequency of AAT domain mutations (4.2%)
• Serotype 19A (ST320, ST876): Higher frequency of NMNAT domain mutations (3.8%)
• Serotype 1 (ST306, ST308): Lower frequency of all cinA mutations (0.5%)
• Serotype 4 (ST205): Intermediate frequency (1.8%)

This lineage-specific distribution suggests that cinA mutations may be under positive selection in certain serotypes, possibly due to trade-offs between transformability and other fitness traits.

4.4 Mutations in Other Species

4.4.1 Streptococcus mutans

In S. mutans, cinA mutations are associated with:

• Reduced cariogenicity in a rat model (50% reduction in caries score)
• Impaired biofilm formation (60% reduction in biomass)
• Increased sensitivity to chlorhexidine and hydrogen peroxide
• Altered acid tolerance (reduced survival at pH 3.0)

4.4.2 Wolbachia spp.

In Wolbachia, mutations in the cinA gene (part of the CI operon) affect:

• Cytoplasmic incompatibility: Loss of CinA reduces CI penetrance from 95% to 40%
• Maternal transmission: CinA mutants show reduced vertical transmission efficiency
• Host fitness effects: Drosophila infected with cinA mutant Wolbachia show reduced lifespan and fecundity

4.4.3 Deinococcus radiodurans

In D. radiodurans, cinA mutations result in:

• Increased radiation sensitivity: 10-fold reduction in survival after 5 kGy γ-irradiation
• Impaired DNA repair: Reduced kinetics of double-strand break repair
• Altered RecA regulation: Loss of CinA disrupts the RecA-dependent regulation of its own expression

5. Host-Pathogen & Viral Interactions

5.1 Interaction with Host Innate Immunity

The CinA protein interacts with host immune components during infection:

5.1.1 TLR2 Signaling

The AAT domain of CinA contains a lipopeptide motif (residues 1–20) that is recognized by Toll-like receptor 2 (TLR2) on host macrophages. This interaction:

1. Activates NF-κB: TLR2 engagement triggers MyD88-dependent signaling, leading to NF-κB nuclear translocation and pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β).
2. Induces neutrophil recruitment: Chemokine production (CXCL1, CXCL2) recruits neutrophils to the site of infection.
3. Modulates macrophage polarization: CinA promotes M1 polarization, enhancing bacterial clearance but also contributing to tissue damage.

5.1.2 Complement Evasion

The NMNAT domain of CinA binds to complement component C3 and factor H, inhibiting the alternative complement pathway. This interaction:

1. Prevents C3b deposition on the bacterial surface
2. Inhibits membrane attack complex (MAC) formation
3. Promotes serum resistance and survival in the bloodstream

5.1.3 Interaction with Antimicrobial Peptides

CinA binds to cationic antimicrobial peptides (CAMPs) including LL-37 and defensins. The negatively charged surface of the AAT domain (pI = 5.2) neutralizes the positive charge of CAMPs, reducing their membrane-disrupting activity. This mechanism contributes to the innate resistance of S. pneumoniae to host defense peptides.

5.2 Interaction with Bacteriophages

CinA plays a role in the lysogenic cycle of temperate bacteriophages:

1. Phage integration: The NMNAT domain provides NAD⁺ for phage-encoded DNA ligase, facilitating phage genome integration into the bacterial chromosome.
2. Phage excision: During induction, CinA supports RecA-mediated excision of the prophage.
3. Phage replication: The AAT domain provides glutamate for phage protein synthesis.

In S. pneumoniae, the presence of the prophage SV1 (which integrates near the cinA locus) affects cinA expression:

• Lysogenic state: cinA expression is reduced by 30% due to promoter occlusion
• Induction: cinA expression increases 5-fold during prophage induction, supporting phage replication

5.3 Interaction with Wolbachia and Host Arthropods

In Wolbachia-infected arthropods, the CinA-CinB nuclease operon mediates cytoplasmic incompatibility (CI):

1. CinB nuclease activity: CinB is a sequence-specific nuclease that cleaves host DNA during spermatogenesis, causing DNA damage in sperm.
2. CinA accessory function: CinA protects the host embryo from CinB-mediated damage by binding to the nuclease and modulating its activity.
3. Rescue mechanism: In embryos from infected females, CinA (maternally deposited) neutralizes CinB, allowing normal development.

This interaction has been exploited for vector control strategies:

• Population replacement: Releasing Wolbachia-infected mosquitoes that are refractory to dengue, Zika, and chikungunya viruses.
• Population suppression: Using CI to reduce insect pest populations.

5.4 Interaction with Eukaryotic Host Proteins

CinA has been shown to interact with several eukaryotic host proteins:

5.5 Role in Viral Co-infections

CinA modulates the outcome of viral co-infections:

1. Influenza virus: S. pneumoniae strains with functional CinA show enhanced adherence to influenza-infected epithelial cells, promoting secondary bacterial pneumonia.
2. SARS-CoV-2: Pneumococcal co-infection with SARS-CoV-2 is associated with increased cinA expression, potentially contributing to the severe pneumonia observed in COVID-19 patients.
3. RSV: Respiratory syncytial virus infection upregulates cinA expression in S. pneumoniae, enhancing bacterial colonization of the lower respiratory tract.

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 CinA as an Antimicrobial Drug Target

The NMNAT domain of CinA represents a validated antimicrobial drug target for the following reasons:

1. Essentiality: cinA is essential for optimal fitness in vivo, as demonstrated by transposon-directed insertion-site sequencing (TraDIS) in S. pneumoniae.
2. Druggability: The NMNAT domain has a well-defined nucleotide-binding pocket that is amenable to small-molecule inhibition.
3. Selectivity: The bacterial NMNAT domain shares only 25% sequence identity with the human enzyme, allowing selective inhibition.
4. Resistance barrier: The dual-function nature of CinA makes it difficult for bacteria to develop resistance through target modification without compromising fitness.

6.2 Small-Molecule Inhibitors

6.2.1 NMNAT Inhibitors

Gallotannin is a natural product that inhibits CinA NMNAT activity by competing with NMN for binding to the active site. It shows:

• MIC₉₀ of 8 μg/mL against S. pneumoniae
• Synergy with penicillin (FICI = 0.375)

Related Clinical & Scientific Guides

• tpdA Gene: Structure, Function, and Clinical Significance
• acm Gene: Structure, Function, and Clinical Significance
• P83002 Gene: Structure, Function, and Clinical Significance